MLTX MoonLake Immunotherapeutics
$11.41
MoonLake Immunotherapeutics (MLTX) Earnings News
Earnings press releases, previews and reviews for MoonLake Immunotherapeutics (MLTX), newest first.
Monday
August 10, 2026
7:00 AM ET
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Sunday
May 10, 2026
9:00 AM ET
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results